Skip to main content

Joltid

Popular

ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics

SAN DIEGO, June 22, 2026 /PRNewswire/ — ChemDiv, Inc. (www.chemdiv.com), a global provider of integrated drug discovery solutions, today announced significant milestones achieved through its proprietary central nervous system (CNS) focused drug discovery platform. The ChemDiv-built platform has…

Read the full release →

News provided by PR Newswire.